Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis

The authors present a removable vena cava filter that may be introduced percutaneously, is atraumatic to the venous wall, and permits the simultaneous use of thrombolytic therapy. Sixty-five patients were studied: 42 cases of pulmonary embolism with threatening venous thrombosis; 23 cases of phlebit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 1990-04, Vol.11 (4), p.334
Hauptverfasser: Thery, C, Asseman, P, Amrouni, N, Becquart, J, Pruvost, P, Lesenne, M, Legghe, R, Marache, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 334
container_title European heart journal
container_volume 11
creator Thery, C
Asseman, P
Amrouni, N
Becquart, J
Pruvost, P
Lesenne, M
Legghe, R
Marache, P
description The authors present a removable vena cava filter that may be introduced percutaneously, is atraumatic to the venous wall, and permits the simultaneous use of thrombolytic therapy. Sixty-five patients were studied: 42 cases of pulmonary embolism with threatening venous thrombosis; 23 cases of phlebitis associated with an ilio-caval thrombus without pulmonary embolism. The filter was introduced 38 times femorally and 27 times by a jugular approach. In 16 cases (24.6%) clots broke loose, were effectively caught by the filter, and were progressively dissolved during thrombolytic therapy. The filter remained in place on average 4.5 +/- 1.2 days. The filter was removed in all cases without provoking the recurrence of pulmonary embolism. Two deaths, not related to pulmonary embolism, occurred during hospitalization. Phlebography, performed in all cases before and after treatment, showed a significant decrease of the phlebographic score (10.88 +/- 0.82 vs 6.77 +/- 0.86, P less than 0.001). The same was observed in 40 patients who underwent a pulmonary angiography before and after treatment (Miller index = 17.04 +/- 0.73 vs 5.49 +/- 0.87, P less than 0.0001). After removal of the filter, no sign of pulmonary embolism was detected on lung scan in the 23 patients with ilio-caval thrombus alone. More than 5 g (100 ml)-1 of haemoglobin was lost by 15.38% of patients. All patients were followed-up for a mean of 7.12 +/- 1.3 months; in no case was there any clinical recurrence of pulmonary embolism. Thus this device allows an effective temporary filtering of the vena cava.
doi_str_mv 10.1093/oxfordjournals.eurheartj.a059707
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_2331999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2331999</sourcerecordid><originalsourceid>FETCH-LOGICAL-g230t-fb0f7e402c15179118716308a26a66868c6c6193cf37cd5e70e151c2a0edce173</originalsourceid><addsrcrecordid>eNotj81OwzAQhH0AlVJ4BCQfuaSsY2LHR1TxJ1XiQiVuleOsqaskjmyn0LfHFT3tSjOz-w0h9wyWDBR_8L_Wh3bvpzDoLi5xCjvUIe2XGiolQV6QOTBVFULUX1fkOsY9ANSCiRmZlZwzpdScpE1E6i3VdMAfGrD3B910SA84aGr0QVPruoSBuoHmb3lJno4Bs57oOHW9H3Q4Uuwb37nYn2yjTi6rkcap6V1K2J4yaRf8yXSMLt6QS5uR8fY8F2Tz8vy5eivWH6_vq6d18V1ySIVtwEp8hNKwiknFWC2Z4FDrUuhcStRGGMEUN5ZL01YoAbPRlBqwNcgkX5C7_7tjJsF2OwbXZ9rtuT3_A96qZK0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis</title><source>Oxford University Press Journals Digital Archive legacy</source><source>MEDLINE</source><creator>Thery, C ; Asseman, P ; Amrouni, N ; Becquart, J ; Pruvost, P ; Lesenne, M ; Legghe, R ; Marache, P</creator><creatorcontrib>Thery, C ; Asseman, P ; Amrouni, N ; Becquart, J ; Pruvost, P ; Lesenne, M ; Legghe, R ; Marache, P</creatorcontrib><description>The authors present a removable vena cava filter that may be introduced percutaneously, is atraumatic to the venous wall, and permits the simultaneous use of thrombolytic therapy. Sixty-five patients were studied: 42 cases of pulmonary embolism with threatening venous thrombosis; 23 cases of phlebitis associated with an ilio-caval thrombus without pulmonary embolism. The filter was introduced 38 times femorally and 27 times by a jugular approach. In 16 cases (24.6%) clots broke loose, were effectively caught by the filter, and were progressively dissolved during thrombolytic therapy. The filter remained in place on average 4.5 +/- 1.2 days. The filter was removed in all cases without provoking the recurrence of pulmonary embolism. Two deaths, not related to pulmonary embolism, occurred during hospitalization. Phlebography, performed in all cases before and after treatment, showed a significant decrease of the phlebographic score (10.88 +/- 0.82 vs 6.77 +/- 0.86, P less than 0.001). The same was observed in 40 patients who underwent a pulmonary angiography before and after treatment (Miller index = 17.04 +/- 0.73 vs 5.49 +/- 0.87, P less than 0.0001). After removal of the filter, no sign of pulmonary embolism was detected on lung scan in the 23 patients with ilio-caval thrombus alone. More than 5 g (100 ml)-1 of haemoglobin was lost by 15.38% of patients. All patients were followed-up for a mean of 7.12 +/- 1.3 months; in no case was there any clinical recurrence of pulmonary embolism. Thus this device allows an effective temporary filtering of the vena cava.</description><identifier>ISSN: 0195-668X</identifier><identifier>DOI: 10.1093/oxfordjournals.eurheartj.a059707</identifier><identifier>PMID: 2331999</identifier><language>eng</language><publisher>England</publisher><subject>Catheters, Indwelling ; Female ; Humans ; Male ; Micropore Filters ; Middle Aged ; Phlebography ; Pulmonary Artery - diagnostic imaging ; Pulmonary Embolism - diagnostic imaging ; Pulmonary Embolism - drug therapy ; Pulmonary Embolism - therapy ; Recurrence ; Streptokinase - therapeutic use ; Thrombolytic Therapy - adverse effects ; Thrombolytic Therapy - methods ; Urokinase-Type Plasminogen Activator - therapeutic use ; Venae Cavae</subject><ispartof>European heart journal, 1990-04, Vol.11 (4), p.334</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2331999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thery, C</creatorcontrib><creatorcontrib>Asseman, P</creatorcontrib><creatorcontrib>Amrouni, N</creatorcontrib><creatorcontrib>Becquart, J</creatorcontrib><creatorcontrib>Pruvost, P</creatorcontrib><creatorcontrib>Lesenne, M</creatorcontrib><creatorcontrib>Legghe, R</creatorcontrib><creatorcontrib>Marache, P</creatorcontrib><title>Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>The authors present a removable vena cava filter that may be introduced percutaneously, is atraumatic to the venous wall, and permits the simultaneous use of thrombolytic therapy. Sixty-five patients were studied: 42 cases of pulmonary embolism with threatening venous thrombosis; 23 cases of phlebitis associated with an ilio-caval thrombus without pulmonary embolism. The filter was introduced 38 times femorally and 27 times by a jugular approach. In 16 cases (24.6%) clots broke loose, were effectively caught by the filter, and were progressively dissolved during thrombolytic therapy. The filter remained in place on average 4.5 +/- 1.2 days. The filter was removed in all cases without provoking the recurrence of pulmonary embolism. Two deaths, not related to pulmonary embolism, occurred during hospitalization. Phlebography, performed in all cases before and after treatment, showed a significant decrease of the phlebographic score (10.88 +/- 0.82 vs 6.77 +/- 0.86, P less than 0.001). The same was observed in 40 patients who underwent a pulmonary angiography before and after treatment (Miller index = 17.04 +/- 0.73 vs 5.49 +/- 0.87, P less than 0.0001). After removal of the filter, no sign of pulmonary embolism was detected on lung scan in the 23 patients with ilio-caval thrombus alone. More than 5 g (100 ml)-1 of haemoglobin was lost by 15.38% of patients. All patients were followed-up for a mean of 7.12 +/- 1.3 months; in no case was there any clinical recurrence of pulmonary embolism. Thus this device allows an effective temporary filtering of the vena cava.</description><subject>Catheters, Indwelling</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Micropore Filters</subject><subject>Middle Aged</subject><subject>Phlebography</subject><subject>Pulmonary Artery - diagnostic imaging</subject><subject>Pulmonary Embolism - diagnostic imaging</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Pulmonary Embolism - therapy</subject><subject>Recurrence</subject><subject>Streptokinase - therapeutic use</subject><subject>Thrombolytic Therapy - adverse effects</subject><subject>Thrombolytic Therapy - methods</subject><subject>Urokinase-Type Plasminogen Activator - therapeutic use</subject><subject>Venae Cavae</subject><issn>0195-668X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj81OwzAQhH0AlVJ4BCQfuaSsY2LHR1TxJ1XiQiVuleOsqaskjmyn0LfHFT3tSjOz-w0h9wyWDBR_8L_Wh3bvpzDoLi5xCjvUIe2XGiolQV6QOTBVFULUX1fkOsY9ANSCiRmZlZwzpdScpE1E6i3VdMAfGrD3B910SA84aGr0QVPruoSBuoHmb3lJno4Bs57oOHW9H3Q4Uuwb37nYn2yjTi6rkcap6V1K2J4yaRf8yXSMLt6QS5uR8fY8F2Tz8vy5eivWH6_vq6d18V1ySIVtwEp8hNKwiknFWC2Z4FDrUuhcStRGGMEUN5ZL01YoAbPRlBqwNcgkX5C7_7tjJsF2OwbXZ9rtuT3_A96qZK0</recordid><startdate>19900401</startdate><enddate>19900401</enddate><creator>Thery, C</creator><creator>Asseman, P</creator><creator>Amrouni, N</creator><creator>Becquart, J</creator><creator>Pruvost, P</creator><creator>Lesenne, M</creator><creator>Legghe, R</creator><creator>Marache, P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19900401</creationdate><title>Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis</title><author>Thery, C ; Asseman, P ; Amrouni, N ; Becquart, J ; Pruvost, P ; Lesenne, M ; Legghe, R ; Marache, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g230t-fb0f7e402c15179118716308a26a66868c6c6193cf37cd5e70e151c2a0edce173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Catheters, Indwelling</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Micropore Filters</topic><topic>Middle Aged</topic><topic>Phlebography</topic><topic>Pulmonary Artery - diagnostic imaging</topic><topic>Pulmonary Embolism - diagnostic imaging</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Pulmonary Embolism - therapy</topic><topic>Recurrence</topic><topic>Streptokinase - therapeutic use</topic><topic>Thrombolytic Therapy - adverse effects</topic><topic>Thrombolytic Therapy - methods</topic><topic>Urokinase-Type Plasminogen Activator - therapeutic use</topic><topic>Venae Cavae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thery, C</creatorcontrib><creatorcontrib>Asseman, P</creatorcontrib><creatorcontrib>Amrouni, N</creatorcontrib><creatorcontrib>Becquart, J</creatorcontrib><creatorcontrib>Pruvost, P</creatorcontrib><creatorcontrib>Lesenne, M</creatorcontrib><creatorcontrib>Legghe, R</creatorcontrib><creatorcontrib>Marache, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thery, C</au><au>Asseman, P</au><au>Amrouni, N</au><au>Becquart, J</au><au>Pruvost, P</au><au>Lesenne, M</au><au>Legghe, R</au><au>Marache, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>1990-04-01</date><risdate>1990</risdate><volume>11</volume><issue>4</issue><spage>334</spage><pages>334-</pages><issn>0195-668X</issn><abstract>The authors present a removable vena cava filter that may be introduced percutaneously, is atraumatic to the venous wall, and permits the simultaneous use of thrombolytic therapy. Sixty-five patients were studied: 42 cases of pulmonary embolism with threatening venous thrombosis; 23 cases of phlebitis associated with an ilio-caval thrombus without pulmonary embolism. The filter was introduced 38 times femorally and 27 times by a jugular approach. In 16 cases (24.6%) clots broke loose, were effectively caught by the filter, and were progressively dissolved during thrombolytic therapy. The filter remained in place on average 4.5 +/- 1.2 days. The filter was removed in all cases without provoking the recurrence of pulmonary embolism. Two deaths, not related to pulmonary embolism, occurred during hospitalization. Phlebography, performed in all cases before and after treatment, showed a significant decrease of the phlebographic score (10.88 +/- 0.82 vs 6.77 +/- 0.86, P less than 0.001). The same was observed in 40 patients who underwent a pulmonary angiography before and after treatment (Miller index = 17.04 +/- 0.73 vs 5.49 +/- 0.87, P less than 0.0001). After removal of the filter, no sign of pulmonary embolism was detected on lung scan in the 23 patients with ilio-caval thrombus alone. More than 5 g (100 ml)-1 of haemoglobin was lost by 15.38% of patients. All patients were followed-up for a mean of 7.12 +/- 1.3 months; in no case was there any clinical recurrence of pulmonary embolism. Thus this device allows an effective temporary filtering of the vena cava.</abstract><cop>England</cop><pmid>2331999</pmid><doi>10.1093/oxfordjournals.eurheartj.a059707</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 1990-04, Vol.11 (4), p.334
issn 0195-668X
language eng
recordid cdi_pubmed_primary_2331999
source Oxford University Press Journals Digital Archive legacy; MEDLINE
subjects Catheters, Indwelling
Female
Humans
Male
Micropore Filters
Middle Aged
Phlebography
Pulmonary Artery - diagnostic imaging
Pulmonary Embolism - diagnostic imaging
Pulmonary Embolism - drug therapy
Pulmonary Embolism - therapy
Recurrence
Streptokinase - therapeutic use
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
Urokinase-Type Plasminogen Activator - therapeutic use
Venae Cavae
title Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20a%20new%20removable%20vena%20cava%20filter%20in%20order%20to%20prevent%20pulmonary%20embolism%20in%20patients%20submitted%20to%20thrombolysis&rft.jtitle=European%20heart%20journal&rft.au=Thery,%20C&rft.date=1990-04-01&rft.volume=11&rft.issue=4&rft.spage=334&rft.pages=334-&rft.issn=0195-668X&rft_id=info:doi/10.1093/oxfordjournals.eurheartj.a059707&rft_dat=%3Cpubmed%3E2331999%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2331999&rfr_iscdi=true